Evandro de Azambuja
Impact in
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
Papers in
- Oncology 233
- HER2/EGFR in Cancer Research 142
- Cancer Treatment and Pharmacology 70
- Cancer Risks and Factors 18
- Cancer Research 108
- Breast Cancer Treatment Studies 97
- Cancer Genomics and Diagnostics 14
- Co-authors
- Martine Piccart (167 shared papers)Christos Sotiriou (45 shared papers)Matteo Lambertini (79 shared papers)Giuseppe Viale (25 shared papers)Hatem A. Azim (23 shared papers)Sherene Loi (22 shared papers)Gilberto de Castro (6 shared papers)Fátima Cardoso (17 shared papers)
- Journals
- Journal of Clinical Oncology (51 papers)Annals of Oncology (43 papers)ESMO Open (34 papers)European Journal of Cancer (19 papers)Cancer Research (18 papers)
- Partner nations
- BelgiumItalyUnited States
In The Last Decade
Evandro de Azambuja
334 papers receiving 15.5k citations
Evandro de Azambuja's Hit Papers
Peers
Comparison fields: 5 of 154
- Oncology 8.2k
- Cancer Research 3.5k
- Pulmonary and Respiratory Medicine 2.7k
- Radiology, Nuclear Medicine and Imaging 1.8k
- Cardiology and Cardiovascular Medicine 1.3k
Countries citing papers authored by Evandro de Azambuja
This map shows the geographic impact of Evandro de Azambuja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evandro de Azambuja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evandro de Azambuja more than expected).
Fields of papers citing papers by Evandro de Azambuja
This network shows the impact of papers produced by Evandro de Azambuja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evandro de Azambuja. The network helps show where Evandro de Azambuja may publish in the future.
Co-authors
The 25 scholars most cited alongside Evandro de Azambuja, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 357 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 Hit paper breakdown → | 2013 | 1231 |
| 2 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer Hit paper breakdown → | 2017 | 940 |
| 3 | Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients Hit paper breakdown → | 2007 | 734 |
| 4 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Hit paper breakdown → | 2017 | 704 |
| 5 | Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Hit paper breakdown → | 2012 | 607 |
| 6 | EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours Hit paper breakdown → | 2017 | 441 |
| 7 | Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab Hit paper breakdown → | 2015 | 439 |
| 8 | 2012 | 360 | |
| 9 | 2013 | 318 | |
| 10 | 2018 | 311 | |
| 11 | 2014 | 302 | |
| 12 | 2014 | 301 | |
| 13 | 2007 | 261 | |
| 14 | 2005 | 230 | |
| 15 | 2011 | 218 | |
| 16 | 2020 | 209 | |
| 17 | Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer Hit paper breakdown → | 2021 | 184 |
| 18 | 2014 | 182 | |
| 19 | HER2-Low Breast Cancer: Molecular Characteristics and Prognosis Hit paper breakdown → | 2021 | 181 |
| 20 | 2010 | 179 |
About Evandro de Azambuja
Evandro de Azambuja is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 357 papers that have together received 15.8k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (142 papers), Breast Cancer Treatment Studies (97 papers), Advanced Breast Cancer Therapies (72 papers), Cancer Treatment and Pharmacology (70 papers), Monoclonal and Polyclonal Antibodies Research (27 papers), Chemotherapy-induced cardiotoxicity and mitigation (20 papers), Cancer Risks and Factors (18 papers) and Cancer Genomics and Diagnostics (14 papers). The work is most often cited by research in Oncology (8.2k citations), Cancer Research (3.5k citations), Pulmonary and Respiratory Medicine (2.7k citations), Radiology, Nuclear Medicine and Imaging (1.8k citations) and Cardiology and Cardiovascular Medicine (1.3k citations). Evandro de Azambuja has collaborated with scholars based in Belgium, Italy and United States. Frequent co-authors include Martine Piccart, Christos Sotiriou, Matteo Lambertini, Giuseppe Viale, Hatem A. Azim, Sherene Loi, Gilberto de Castro, Fátima Cardoso, Marianne Paesmans and Richard D. Gelber. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, ESMO Open, European Journal of Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.